Ranbaxy Laboratories Ltd Presented by Sudip & Pradipta

Company Highlights Largest pharmaceutical company FDA inspected and approved facilities. Expertise in diverse categories Expertise in OTC Strengths and vibrancy Other Expertise

Largest pharmaceutical company

FDA inspected and approved facilities.

Expertise in diverse categories

Expertise in OTC

Strengths and vibrancy

Other Expertise

Timelines 1962: Ranjit Singh and Gurbux Singh in Amritsar 1977: First JV Nigeria 1987: State-of-the-art API facility in Toansa in preparation for entry into the U.S. market, receives FDA approval in 1988 1992: Launches a joint marketing agreement with Eli Lilly 1993: A joint venture is launched in China; a new research-driven NCE and NDDS strategy launched 1995: The company acquires Ohm Laboratories in the United States and builds a new FDA-approved production facility 2000: A cquires Basics, Bayer's generics business in Germany; the company enters Brazil 2003 : Acquires Aventis in France Latest : Wish to acquire $2 Billion stake in Merck

1962: Ranjit Singh and Gurbux Singh in Amritsar

1977: First JV Nigeria

1987: State-of-the-art API facility in Toansa in preparation for entry

into the U.S. market, receives FDA approval in 1988

1992: Launches a joint marketing agreement with Eli Lilly

1993: A joint venture is launched in China; a new research-driven

NCE and NDDS strategy launched

1995: The company acquires Ohm Laboratories in the United

States and builds a new FDA-approved production facility

2000: A cquires Basics, Bayer's generics business in Germany; the

company enters Brazil

2003 : Acquires Aventis in France

Latest : Wish to acquire $2 Billion stake in Merck

Internationalization

International Biz USA Largest Healthcare market Entered in 1995, now the largest market for the company Acquire Ohm labs 28% of Ranbaxy’s revenues 96 products approved by FDA

USA

Largest Healthcare market

Entered in 1995, now the largest market for the company

Acquire Ohm labs

28% of Ranbaxy’s revenues

96 products approved by FDA

ITALY(GSK) & SPAIN Organic opportunities. Bought Allen in Italy Among top 10 global market. Low penetration on generics. Patents expiries happen later. First movers advantage.

ITALY(GSK) & SPAIN

Organic opportunities.

Bought Allen in Italy

Among top 10 global market.

Low penetration on generics.

Patents expiries happen later.

First movers advantage.

BELGIUM (Ethimed) High priced and profitable market. Market is not too large. Existence of 10-12 products.

BELGIUM (Ethimed)

High priced and profitable market.

Market is not too large.

Existence of 10-12 products.

ROMANIA (Terapia) Low cost market in terms of manufacturing. Strategically well positioned. Wide marketing authorizations. Strong product portfolio. Strong field force

ROMANIA (Terapia)

Low cost market in terms of manufacturing.

Strategically well positioned.

Wide marketing authorizations.

Strong product portfolio.

Strong field force

Managing the business Created trade support & networks overseas Confidence in generic drug business Germany 4.8 UK 2.8 France 1.6 Italy 0.5 (major size of generics market in $ billion)

Created trade support & networks overseas

Confidence in generic drug business

Germany 4.8

UK 2.8

France 1.6

Italy 0.5

(major size of generics market in $ billion)

Cont… Allowed to diverse into new markets Intangible assets

Allowed to diverse into new markets

Intangible assets

Thank You

Thank You